Synergy Pharma (SGYP) Tops Q2 EPS by 6c, Beats on Revenues

Synergy Pharma (NASDAQ: SGYP) reported Q2 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $5 million versus the consensus estimate of $4.53 million.

For earnings history and earnings-related data on Synergy Pharma (SGYP) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance